Recent Comments

Comment RSS

Business / Finance RSS Feed - Business / Finance

Synutra International announces revenues of $96.80M for third-quarter ended December 31, 2009

9. February 2010 09:05
Synutra International, Inc., a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today reported financial results for the Company’s third quarter and nine months ended December 31, 2009. [More]

Posted in: Business / Finance

Tags: ,

Fourth-quarter and full-year 2009 results announced by Cynosure

9. February 2010 08:48
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009. [More]

Posted in: Business / Finance

Tags:

Nu Skin Enterprises declares quarterly cash dividend of $0.125 per share

9. February 2010 08:32
Nu Skin Enterprises, Inc. today announced that its board of directors declared a 9 percent increase in the quarterly cash dividend to $0.125 per share. Annually, this would increase the dividend to $0.50, up from $0.46 in the prior year. The increase begins in the first quarter and will be paid on March 17, 2010, to shareholders of record on Feb. 26, 2010. [More]

Posted in: Business / Finance

Tags:

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

9. February 2010 08:10
Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore. [More]

Posted in: Business / Finance | Device / Technology News

Tags: , , , ,

Hoya reports financial results for quarter ended December 31, 2009

9. February 2010 08:06
Hoya Corporation today announced financial results for the third quarter ended December 31, 2009. Net sales were 106.8 billion yen for the quarter, a 5.2% decrease from 112.7 billion yen in the same period last year. Operating income was 18.9 billion yen, a 13.8% increase from 16.6 billion yen in the same period last year, mainly due to increase in orders and productivity. Compared to the second quarter ended September 30, 2009, sustained recovery in orders since April resulted in an increase of both net sales and operating income. [More]

Posted in: Business / Finance

Tags:

LCA-Vision announces fourth quarter 2009 operational and financial results

9. February 2010 07:49
LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three and 12 month periods ended December 31, 2009. [More]

Posted in: Business / Finance

Tags:

Biogen Idec reports 2009 fourth quarter and full year earnings

9. February 2010 07:45
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results. [More]

Fourth-quarter and full-year 2009 results announced by Compugen

9. February 2010 07:43
Compugen Ltd. today reported financial results for the fourth quarter and year ending December 31, 2009. [More]

Triple-S Management reports consolidated revenues of $516.9 million for fourth-quarter 2009

9. February 2010 07:38
Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated revenues of $516.9 million and operating income of $34.2 million for the three months ended December 31, 2009. [More]

Posted in: Business / Finance

Tags: , , ,

Third-quarter fiscal 2010 results announced by Clinical Data

9. February 2010 07:38
Clinical Data, Inc. (NASDAQ: CLDA) today announced the Company’s operational and financial results for its third fiscal quarter ended December 31, 2009, confirming its plans to submit a new drug application (NDA) for vilazodone for the treatment of depression this quarter. [More]

Targeted Genetics receives milestone payments from Genzyme and Amsterdam Molecular Therapeutics

9. February 2010 07:04
Targeted Genetics Corporation (the “Company”) today announced that it has completed the technology transfer portion of the September 2009 asset sale transaction executed between the Company and Genzyme Corporation (“Genzyme”) and has received the full $7.0 million provided for in the asset purchase agreement. [More]

Posted in: Business / Finance

Tags: , ,

Coventry Health Care reports revenues of $3.4 billion for fourth-quarter 2009

9. February 2010 06:59
Coventry Health Care, Inc. today reported consolidated operating results for the quarter ended December 31, 2009. Operating revenues totaled $3.4 billion for the quarter with net earnings of $109.1 million, or $0.74 earnings per diluted share (EPS). For the year ended December 31, 2009, total revenues from continuing operations were $13.9 billion with net earnings from continuing operations of $315.3 million, or $2.14 per diluted share. [More]

Posted in: Business / Finance

Tags: , ,

Centene announces fourth quarter and full year 2009 financial results

9. February 2010 06:49
Centene Corporation today announced its financial results for the quarter and year ended December 31, 2009. The results of operations for our New Jersey health plan, University Health Plans, are classified as discontinued operations. [More]

Posted in: Business / Finance

Tags: , ,

Sanofi-aventis completes tender offer for Chattem common stock

9. February 2010 05:17
Sanofi-aventis announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc.. [More]

Posted in: Business / Finance

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

9. February 2010 04:41
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan. [More]

Posted in: Business / Finance | Drug Trial News | Disease/Infection News

Tags: , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.